SynthesisMedicine2026
Effect of dual antiplatelet therapy on prognosis of patients with myocardial infarction with nonobstructive coronary artery disease: A meta-analysis.
Synthesis in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe diverse pathogenic mechanisms of myocardial infarction with nonobstructive coronary artery disease (MINOCA) result in therapeutic difficulties. The purpose of this meta-analysis was to assess the impact of dual antiplatelet therapy (DAPT) on prognosis of patients with MINOCA.
methodsRelevant studies published prior to May 2025 were identified through a search of the PubMed, Embase and Web of Science databases. We evaluated the data using hazard ratios (HRs) and 95% confidence interval (CI). Heterogeneity among studies was assessed by I2 and Cochran's Q test. To identify the sources of heterogeneity, subgroup analysis was conducted according to the predefined criteria.
resultsSix studies enrolling 13,027 patients with MINOCA were pooled in the meta-analysis. After 48 months of follow-up, DAPT showed no significant association with a reduced risk of major adverse cardiovascular events (HR = 1.00; 95% CI, 0.71-1.41; P = .985). Aggregate data from 4 studies indicated that DAPT was associated with a significant reduction of all-cause death (HR = 0.76; 95% CI, 0.60-0.96; P = .021). However, results from 3 studies regarding myocardial infarction were not statistically significant (HR = 1.03; 95% CI, 0.72-1.45; P = .885).
conclusionOur findings suggest that while DAPT offers a survival benefit for MINOCA patients, it does not reduce the risk of major adverse cardiovascular events and myocardial infarction. Further large randomized controlled trials are required to evaluate individual treatment based on the different etiologies of MINOCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.